MIR424 (MicroRNA 424)

ADRB2 overexpression inhibited tumor growth, enhanced immune cell infiltration, and was positively correlated with immune checkpoint markers such as PD-1 and PD-L1. These findings provide a basis for developing novel LUAD treatment strategies focusing on immune modulation through ADRB2-targeted interventions.

Integrating tissue-derived molecular miRNA signatures with existing clinical risk models may enhance the prediction of HCC recurrence following LT. Incorporating molecular approaches into current protocols could refine post-transplant risk stratification and surveillance guidance.

These results underscore the tumor-suppressive role of the miR-424(322)~503 cluster in CRC by modulating key oncogenic pathways such as MAPK and TGFβ. Our study provides novel insights into the interplay between PTEN loss and miRNA regulation in CRC pathogenesis.

These findings unveil an oncogenic role of miR-424-5p in HBV-HCC, suggesting its function is driven by viral specific dysregulation of the PI3K/AKT pathway, with PTEN involvement. Our study highlights miR-424-5p as a potential therapeutic target and provides insights into etiology-specific miRNA regulatory networks.

Therefore, these findings suggest that miRNAs may serve as predictive biomarkers and potential therapeutic targets in the management of breast cancer.

A multivariate logistic regression combining miR-21, miR-31, miR-146a, and miR-424 yielded an AUC of 0.959, 96.7% specificity, and 86.7% sensitivity. Although limited by sample size, this study provides the first step for larger validation studies aimed at confirming the diagnostic utility of our salivary four-miRNA signature as a cost-effective and minimally invasive diagnostic tool for OSCC.

This review explores their multifaceted functions in cancer immunotherapy: in TME, tumor-derived exosomes (TDEs) drive immunosuppression, cancer-associated fibroblasts(CAFs) activation, and angiogenesis to promote progression and immune checkpoint inhibitors (ICIs) resistance; diagnostically, exosomal biomolecules (e.g., urinary miR-424/423/660/let-7i, serum LINC01125) serve as sensitive liquid biopsy markers for early detection and monitoring; therapeutically, engineered exosomes (e.g., DC-derived antigen-loaded ones) activate antitumor immunity and reverse ICIs resistance. These findings highlight exosomes' potential as diagnostic and therapeutic tools, laying a foundation for personalized cancer treatment.

[This retracts the article DOI: 10.2147/OTT.S280717.].

[This retracts the article DOI: 10.2147/CMAR.S185789.].

Furthermore, the absence of miR-424(322)~503 restores TGFβ-induced apoptosis, which is otherwise compromised by PTEN deficiency. In vivo, Pten/miR-424(322)~503 knock-out mice exhibit reduced endometrial cancer progression compared to Pten deficient mice through a cell-autonomous mechanism.

Pathway enrichment analysis highlighted KRAS, ESR1, ESR2, RAB10, TNRC6C, and NCAN as the most commonly differentially expressed in EA, whereas ERBB4, PLCB1, and SERPINE1 were most frequently in AA. These findings highlight the importance of considering race-specific miRNA-mRNA signatures in understanding TNBC in the context of obesity, offering insights into biomarker-driven patient stratification for targeted therapeutic strategies.